Navigation Links
Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
Date:12/7/2007

HAYWARD, Calif., Dec. 7 /PRNewswire/ -- Acologix, Inc., a privately held biopharmaceutical company, today announced preclinical study results demonstrating that AC-100, its novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells, promoted cartilage regeneration in an animal model. The data was presented by Dr. Catherine Middleton-Hardie at the Osteoarthritis Research Society International (OARSI) 2007 World Congress on Osteoarthritis in Fort Lauderdale, Florida during the poster sessions.

In this study, goats with an osteochondral femoral condylar (knee cartilage) defect were used to evaluate the effects of AC-100 on cartilage regeneration. Cylindrical defects were created in the knee cartilage and were filled with a collagen sponge containing AC-100 at two different doses or a collagen sponge soaked in saline (control group). Post-operative treatments included intra-articular injections of the test articles into the operated knee joint at weeks one, two and three post surgery. Cartilage regeneration was evaluated in one group after 84 days and 168 days in another group.

The results demonstrated that the application of AC-100 dose dependently promoted cartilage defect repair. The groups treated with the higher dosage of AC-100 had greater healing outcome scores than the saline control groups. As there was no evidence of an inflammatory response, AC-100 demonstrated a favorable safety profile in the study.

These results follow a reported Phase II clinical trial that demonstrated AC-100 stimulates the formation of new dentin (the hard tissue of teeth that protects the tooth pulp and supports the outer enamel) when applied directly to tooth defects (prepared cavities).

"We are very pleased to see this type of response to AC-100 in such a challenging model. This is the first demonstration of AC-100 to promote cartilage repair. These findings are consistent with previous studies where AC-100 ha
'/>"/>

SOURCE Acologix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... LONDON , August 28, 2015 ... seamlessly connects people, technologies and care protoc ... improving outcomes and the cost of healthcare delivery   ... today announced its presence at  ESC Congress 2015 , where the ... A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect people and ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ ... in the commercial development of the company,s supplemental ... Smart Oxygen device, being developed by ieCrowd,s subsidiary ... a patient,s changing demand for oxygen based on ... 510 (k) submission for the Smart Oxygen device ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
... the global leader in technology support and BPO services ... today the opening of its new Global Operations Center ... city of Dalian, will specialize in providing services in ... sponsors and clinical research organizations. With dramatic ...
... ARBOR, Mich., April 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... serious central nervous system diseases, announced today that it has ... its common stock at approximately $2.0725 per share to a ... million in gross proceeds. The investor will also receive warrants ...
Cached Medicine Technology:C3i Opens Asia Language Center in Dalian, China 2Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular ... market and sell Arterosil and Arterosil HP, and that all claims and counterclaims ... Vascular Health Sciences, LLC (VHS) in the United States District Court for the ...
(Date:8/28/2015)... ... 2015 , ... The Kentucky State Department of Workforce Investment Commissioner Beth Kuhn ... applying for, they are unable to pass the initial drug test and therefore unable ... in order to be able to hire long-term, skilled talent. (1) Will Wesch, Director ...
(Date:8/28/2015)... ... , ... As reported by Medical Daily on August 22 , Cellfina, ... last for two years, the longest of any cellulite reduction system currently on the ... long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director of the ...
(Date:8/28/2015)... ... , ... “ Frequentz ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... to track product movement from beginning to end. , Businesses benefit greatly from having ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... three-year accreditation for its adolescent residential, counseling, day treatment and intensive family based ... meets international standards for quality and its pursuit of excellence. As a nonprofit ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... diet/nutrition as leading issue; exercise, physical changes, ... drug use also rank ... report from,the C.S. Mott Children,s Hospital National Poll on Children,s Health ... with kids ages 11 to 17 during routine check-ups. The topics ...
... Davis Collaboration, RANCHO CORDOVA, Calif., Feb. 6 ... supplier of innovative products and,services that process and ... injury, today announced a regenerative medicine initiative in ... wholly-owned subsidiary, Vantus, Inc., a,veterinary stem cell laboratory ...
... first step toward personalized medicine, experts say , , WEDNESDAY, Feb. ... blood test could help a small minority of HIV patients ... can sometimes cause serious side effects. , The test detects ... a patient,s genetic makeup is linked to poor reactions to ...
... multiple risk factors at once, , , WEDNESDAY, Feb. 6 (HealthDay ... showing signs of some kidney damage may be able to ... factors at once. , That,s the conclusion of a ... the New England Journal of Medicine , that found ...
... Burnham Institute for Medical Research (Burnham Institute) have provided ... a suppressor role in skin cancer development. ATF2 ... the first step in the translation of genetic code, ... and ionizing radiation. This function of ATF2 in ...
... has announced the names of the recipients of its annual ... Inder Verma is the prize recipient for biomedical science; the ... The Vilcek Foundation Prizes are awarded annually to foreign-born individuals ... , In explaining the motivation for the awards, Dr. ...
Cached Medicine News:Health News:Parents Identify Health Topics They Want Doctors to Discuss with Kids - New Research for University of Michigan Conducted by Knowledge Networks 2Health News:Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine 2Health News:Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine 3Health News:Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine 4Health News:Test Detects Sensitivity to HIV Drug 2Health News:Aggressive Diabetes Therapy Lowers Death Risk, Study Finds 2Health News:Aggressive Diabetes Therapy Lowers Death Risk, Study Finds 3Health News:Gene found to play a suppressor role in skin cancer development 2Health News:Dr. Inder Verma named recipient of 2008 Vilcek Prize in biomedical science 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: